Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Taylor C. Wallace, Scott Bultman, Chris D’Adamo, Carrie R. Daniel, Justine Debelius, Emily Ho, Heather Eliassen, Dawn Lemanne, Purna Mukherjee, Thomas N. Seyfried, Qiang Tian & Linda T. Vahdat. (2019) Personalized Nutrition in Disrupting Cancer — Proceedings From the 2017 American College of Nutrition Annual Meeting. Journal of the American College of Nutrition 38:1, pages 1-14.
Read now
Read now
Articles from other publishers (20)
Vijay Nayak Bhukya & Durga Prasad Beda. (2024) Implementation of green analytical principles to develop and validate the HPLC method for the separation and identification of degradation products of Panobinostat, and its characterization by using LC-QTOF-MS/MS and its in-silico toxicity prediction using ADMET software. Green Analytical Chemistry 8, pages 100090.
Crossref
Crossref
Michelle Monje, Tabitha Cooney, John Glod, Jie Huang, Cody J Peer, Damien Faury, Patricia Baxter, Kim Kramer, Alicia Lenzen, Nathan J Robison, Lindsay Kilburn, Anna Vinitsky, William D Figg, Nada Jabado, Maryam Fouladi, Jason Fangusaro, Arzu Onar-Thomas, Ira J Dunkel & Katherine E Warren. (2023) Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro-Oncology 25:12, pages 2262-2272.
Crossref
Crossref
Yulia Aleksandrova, Aldar Munkuev, Evgenii Mozhaitsev, Evgeniy Suslov, Konstantin Volcho, Nariman Salakhutdinov & Margarita Neganova. (2023) Hydroxamic Acids Containing a Bicyclic Pinane Backbone as Epigenetic and Metabolic Regulators: Synergizing Agents to Overcome Cisplatin Resistance. Cancers 15:20, pages 4985.
Crossref
Crossref
Jiangkun Yan, Kairui Yue, Xuejing Fan, Ximing Xu, Jing Wang, Mengting Qin, Qianer Zhang, Xiaohan Hou, Xiaoyang Li & Yong Wang. (2023) Synthesis and bioactivity evaluation of ferrocene-based hydroxamic acids as selective histone deacetylase 6 inhibitors. European Journal of Medicinal Chemistry 246, pages 115004.
Crossref
Crossref
Yi Wu, Bo Zhang, Xiaowu Dong, Shenglin Ma & Shengquan Hu. (2022) Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy. Letters in Drug Design & Discovery 19:7, pages 627-636.
Crossref
Crossref
Meilan Hu, Fule He, Erik W. Thompson, Kostya (Ken) Ostrikov & Xiaofeng Dai. (2022) Lysine Acetylation, Cancer Hallmarks and Emerging Onco-Therapeutic Opportunities. Cancers 14:2, pages 346.
Crossref
Crossref
Dongwei Wu, Johanna Berg, Birte Arlt, Viola Röhrs, Munir A. Al-Zeer, Hedwig E. Deubzer & Jens Kurreck. (2021) Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform. International Journal of Molecular Sciences 23:1, pages 122.
Crossref
Crossref
Yi-Wen Wu, Min-Wu Chao, Huang-Ju Tu, Liang-Chieh Chen, Kai-Cheng Hsu, Jing-Ping Liou, Chia-Ron Yang, Shih-Chung Yen, Wei-Chun HuangFu & Shiow-Lin Pan. (2021) A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis 10:5.
Crossref
Crossref
Kunal Nepali & Jing-Ping Liou. (2021) Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. Journal of Biomedical Science 28:1.
Crossref
Crossref
Huanran Sun, Jiaqi Song, Mingming Sun & Changliang Shan. 2021. Epigenetic Regulation in Overcoming Chemoresistance. Epigenetic Regulation in Overcoming Chemoresistance
25
39
.
Pauline Schneider, Patricia Garrido Castro, Sandra M. Pinhanços, Mark Kerstjens, Eddy H. van Roon, Anke H.W. Essing, M. Emmy M. Dolman, Jan J. Molenaar, Rob Pieters & Ronald W. Stam. (2020)
Decitabine mildly attenuates
MLL
‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
. eJHaem 1:2, pages 527-536.
Crossref
Crossref
Magdalena Rausch, Andrea Weiss, Marloes Zoetemelk, Sander R. Piersma, Connie R. Jimenez, Judy R. van Beijnum & Patrycja Nowak-Sliwinska. (2020) Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. Cancers 12:11, pages 3172.
Crossref
Crossref
Di Chen, Zhen Ning, Huan Chen, Chang Lu, Xiaolong Liu, Tian Xia, Huan Qi, Wen Wang, Ting Ling, Xin Guo, Dinesh Singh Tekcham, Xiumei Liu, Jing Liu, Aman Wang, Qiu Yan, Ji-Wei Liu, Guang Tan & Hai-long Piao. (2019) An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases. Oncogene 39:3, pages 587-602.
Crossref
Crossref
Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Efstathios Kastritis, Maria Gavriatopoulou, Evangelos Terpos & Meletios Athanasios Dimopoulos. (2020) Efficacy of Panobinostat for the Treatment of Multiple Myeloma. Journal of Oncology 2020, pages 1-11.
Crossref
Crossref
Fang-I Huang, Yi-Wen Wu, Ting-Yi Sung, Jing-Ping Liou, Mei-Hsiang Lin, Shiow-Lin Pan & Chia-Ron Yang. (2019) MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells. Frontiers in Oncology 9.
Crossref
Crossref
B Rösler, X Wang, S T Keating, L A B Joosten, M G Netea & F L van de Veerdonk. (2018) HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis. Clinical and Experimental Immunology 194:2, pages 205-219.
Crossref
Crossref
Hsueh-Yun Lee, Kunal Nepali, Fang-I Huang, Chih-Yi Chang, Mei-Jung Lai, Yu-Hsuan Li, Hsiang-Ling Huang, Chia-Ron Yang & Jing-Ping Liou. (2018)
(
N
-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma
in Vitro
and
in Vivo
. Journal of Medicinal Chemistry 61:3, pages 905-917.
Crossref
Crossref
Kalpesh Kumar Giri, P. S. Suresh, Syed Mohd Saim, Mohd Zainuddin, Ravi Kanth Bhamidipati, Purushottam Dewang, Mahanandeesha S. Hallur, Sridharan Rajagopal, Sriram Rajagopal & Ramesh Mullangi. (2017) Validation of an LC–MS/MS method for simultaneous detection of four HDAC inhibitors – belinostat, panobinostat, rocilinostat and vorinostat in mouse plasma and its application to a mouse pharmacokinetic study. Biomedical Chromatography 31:7.
Crossref
Crossref
Badar ul Islam & Shams Tabrez. (2017) Management of Alzheimer’s disease—An insight of the enzymatic and other novel potential targets. International Journal of Biological Macromolecules 97, pages 700-709.
Crossref
Crossref
Vanita Chopra, Luisa Quinti, Prarthana Khanna, Paolo Paganetti, Rainer Kuhn, Anne B. Young, Aleksey G. Kazantsev & Steven Hersch. (2016) LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease. Journal of Huntington's Disease 5:4, pages 347-355.
Crossref
Crossref